Standardized peptidome profiling of human serum for the detection of pancreatic cancer

Pancreas

Volumn 39, Issue 8, 2010, Pages 1293-1298

  Zapico Muñiz, Edgar ^a   Farré Viladrich, Antoni ^a   Rico Santana, Nayra ^a   González Sastre, Francesc ^a   Mora Brugués, Josefina ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

biomarkers; CA 19 9; MALDI TOF MS; pancreatic cancer; serum peptide profiling; standardization

Indexed keywords

CA 19-9 ANTIGEN; COPPER ION;

ADOLESCENT; ADULT; AGED; ARTICLE; CHRONIC PANCREATITIS; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; STANDARDIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES; PROTEOMICS; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 78049314897     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181dfcbe5     Document Type: Article

References (28)

1. Jemal A, Seigel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43-66.
2. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581-592.
3. American Gastroenterological Association medical position statement: epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. Gastroenterology. 1999;117:1463-1484.
4. Tascilar M, Skinner HG, Rosty C, et al. The SMAD4 protein and prognosis of pancreatic ductal adenocarcinoma. Clin Cancer Res. 2001;7:4115-4121.
5. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 1995;221:721-731.
6. Lowenfels AB, Maisonneuve P, Cavallini G, et al and International Pancreatitis Study Group. Pancreatitis and the risk of pancreatic cancer. N Engl J Med. 1993;328:1433-1437.
7. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am. 2002;16:37-52.
8. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res. 2000;6:2969-2972.
9. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008; 3:157-188.
10. Sato N, Goggins M. The role of epigenetic alterations in pancreatic cancer. J Hepatobiliary Pancreat Surg. 2006;13:286-295.
11. Hortin GL. The MALDI-TOF mass spectrometric view of plasma proteome and peptidome. Clin Chem. 2006;52:1223-1237.
12. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Cancer Res. 2004;10:860-868.
13. Yu Y, Chen S, Wang LS, et al. Prediction of pancreatic cancer by serum biomarkers using surface-enhanced laser desorption/ionization based decision tree classification. Oncology. 2005;68:79-86.
14. Kojima K, Asmellash S, Klug CA, et al. Applying proteomic-based biomarker tools for the accurate diagnosis of pancreatic cancer. J Gastrointestinal Surg. 2008;12:1683-1690.
15. Karsan A, Eigl BJ, Flibotte S, et al. Analytical and preanalytical biases in serum proteomic pattern analysis for breast cancer diagnosis. Clin Chem. 2005;51:1525-1528.
16. Banks RE, Stanley AJ, Cairns DA, et al. Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem. 2005;51:1637-1649.
17. Semmes OJ, Feng Z, Adam BL, et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem. 2005;51:102-112.
18. Callesen AK, Christensen R, Madsen JS, et al. Reproducibility of serum protein profiling by systematic assessment using solid-phase extraction and matrix-assisted laser desorption/ionization mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:291-300.
19. Villanueva J, Lawlor K, Toledo-Crow R, et al. Automated serum peptide profiling. Nat Protoc. 2006;1:880-891.
20. Albrethsen J. Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin Chem. 2007;53:852-858.
21. Villanueva J, Martorella AJ, Lawlor K, et al. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics. 2006;5:1840-1852.
22. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266-270.
23. Honda K, Hayashida Y, Umaki T, et al. Possible detection of pancreatic cancer by plasma protein profiling. Cancer Res. 2005;65:10613-10622.
24. Navaglia F, Fogar P, Basso D, et al. Pancreatic cancer biomarkers discovery by surface-enhanced laser desorption and ionization time-of-flight mass spectrometry. Clin Chem Lab Med. 2009;47: 713-723.
25. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas. 2007;34:205-214.
26. Fiedler GM, Leichtle AB, Kase J, et al. Serum peptidome profiling revealed platelet factor 4 as a potential discriminating peptide associated with pancreatic cancer. Clin Cancer Res. 2009;15:3812-3819.
27. Diamandis EP. Serum proteomic profiling by matrix-assisted laser desorption-ionization time of flight mass spectrometry for cancer diagnosis: next steps. Cancer Res. 2006;66:5540-5541.
28. Villanueva J, Shaffer DR, Philip J, et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest. 2006;116:271-284.